In spite of all the efforts that has been made in prevention and the success of antiretroviral therapy (ART), AIDS remains a serious public health problem. So, there is a need for development of new antiretrovirals (ARVs) and new therapeutic strategies. New ARVs are currently on advanced stages of clinical evaluation. New therapeutic strategies intend to evaluate the toxicity risk, drug resistance, drug-drug interactions, costs and adherence. Coformulations of fixed-dose drug combination are important advantages of ART that improve adherence, quality of life, evolving to better therapeutic results and reduction of health resources.